TRML
Companies
NASDAQ
Tourmaline Bio Inc.
Health Care
$16.94
-$3.34 (-16.47%)
Price Chart
Overview
About TRML
talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.
Market Cap
$357.3M
Volume
3.6M
Avg. Volume
5.3M
P/E Ratio
-4.2802196
Dividend Yield
109.25%
Employees
76.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.83
Moderate Correlation
Volatility
High (0.81)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, TRML shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025